Barrow Hanley Mewhinney & Strauss LLC Has $288.38 Million Position in Sanofi (NASDAQ:SNY)

Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Sanofi (NASDAQ:SNY) by 113.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 5,943,547 shares of the company’s stock after buying an additional 3,164,092 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned about 0.23% of Sanofi worth $288,381,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of SNY. Sei Investments Co. raised its position in shares of Sanofi by 1.3% in the second quarter. Sei Investments Co. now owns 561,214 shares of the company’s stock valued at $27,230,000 after buying an additional 7,186 shares in the last quarter. AE Wealth Management LLC raised its holdings in Sanofi by 27.9% in the 2nd quarter. AE Wealth Management LLC now owns 17,308 shares of the company’s stock valued at $840,000 after acquiring an additional 3,772 shares in the last quarter. Callan Capital LLC raised its holdings in Sanofi by 90.7% in the 2nd quarter. Callan Capital LLC now owns 9,852 shares of the company’s stock valued at $478,000 after acquiring an additional 4,685 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in shares of Sanofi by 33.6% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 16,737 shares of the company’s stock valued at $812,000 after acquiring an additional 4,207 shares during the period. Finally, ProVise Management Group LLC grew its holdings in shares of Sanofi by 3.2% during the 2nd quarter. ProVise Management Group LLC now owns 176,728 shares of the company’s stock worth $8,575,000 after purchasing an additional 5,509 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 1.1 %

Shares of NASDAQ SNY opened at $57.63 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a 50-day moving average price of $54.34 and a 200-day moving average price of $50.48. The stock has a market capitalization of $145.96 billion, a P/E ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. During the same period last year, the business earned $0.95 EPS. The business’s revenue was up 7.8% on a year-over-year basis. On average, equities research analysts forecast that Sanofi will post 4.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the subject of several analyst reports. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.